Correction: Phase 1 Trial of In Vivo Base-Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia

By
Ping Wan
Siyuan Tang
Dongni Lin
Yuming Lu
Mei Long
Ling Xiao
Yanhong Jiang
Jiaoyang Liao
Xiaoying Ma
Ying Liu
Wensu Yu
Michael Ott
Zi Jun Wang
Yuxuan Wu
Taihua Yang
Qiang Xia
November 3, 2026

Nature Medicine

Objective:

The article examines the objective, findings, and clinical context described in Correction: Phase 1 Trial of In Vivo Base-Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia.

Approach:

Table 1: Corrected baseline ApoB and ApoA1 values for Patients 1–6 after a unit-conversion transcription error had placed entries against neighboring lipid rows.
Extended Data Fig. 2d: Revised the panel and source data to show net background-corrected A-to-G editing frequencies.

Key Findings:

Corrected ApoB values (mg/dL), Patients 1–6: 164, 165, 119, 115, 104, and 171.
Corrected ApoA1 values (mg/dL), Patients 1–6: 159, 174, 117, 157, 140, and 192.
The original figure showed treated-sample A-to-G frequencies before subtraction of matched untreated-control background, although its legend described background-corrected values.

Interpretation:

The correction states that the article’s conclusions, interpretation, results, and safety and efficacy assessments are unchanged.

Conclusion:

Underlying sequencing data, off-target evaluation, eligibility, trial procedures, dosing, treatment delivery, and statistical analyses were unaffected.